Prevention of graft-versus-host-disease with preserved graft-versus- leukemia-effect by ex vivo and in vivo modulation of CD4+ T-cells

Cellular and Molecular Life Sciences

Volumn 71, Issue 11, 2014, Pages 2135-2148

  Fricke, Stephan ^a,b,d   Hilger, Nadja ^a   Fricke, Christian ^c   Schönfelder, Uta ^e   Behre, Gerhard ^d   Ruschpler, Peter ^a   Boldt, Andreas ^b   Oelkrug, Christopher ^a   Sack, Ulrich ^a,b   Emmrich, Frank ^a,b  

^a FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Ambulante Dienste LUPS   (Switzerland)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e Evangelic Diaconic Hospital   (Germany)

Author keywords

Allogeneic hematopoetic stem cell transplantation; Anti CD4 antibodies; GvHD; GvL; Triple transgenic mice

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL RATE; TUMOR ENGRAFTMENT;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; ANTILYMPHOCYTE SERUM; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOMODULATION; LEUKEMIA; MICE; MICE, TRANSGENIC; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 84901679724     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1476-0     Document Type: Article

References (43)

1. Jacobsohn DA, Vogelsang GB (2007) Acute graft versus host disease. Orphan J Rare Dis 2:35
2. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674):1550-1561
3. Hill GR, Krenger W, Ferrara JL (1997) The role of cytokines in acute graft-versus-host disease. Cyto Cell Mol Ther 3(4):257-266
4. Paczesny S, Choi SW, Ferrara JL (2009) Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol 16(6):427-436
5. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Illmer T, Platzbecker U, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhauser M (2009) Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. B Mar Transpl 43(3):245-251
6. Trapani JA, Smyth MJ (2002) Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2(10):735-747
7. Michalek J, Collins RH, Durrani HP, Vaclavkova P, Ruff LE, Douek DC, Vitetta ES (2003) Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4 + T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci USA 100(3):1180-1184
8. Fehervari Z, Cooke A, Brett S, Turner J (2002) Perturbation of naive TCR transgenic T cell functional responses and upstream activation events by anti-CD4 monoclonal antibodies. Eur J Immunol 32(2):333-340
9. Harding S, Lipp P, Alexander DR (2002) A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol 169(1):230-238
10. Madrenas J, Schwartz RH, Germain RN (1996) Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc Natl Acad Sci USA 93(18):9736-9741
11. Madrenas J, Germain RN (1996) Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation. Semin Immunol 8(2):83-101
12. Chatenoud L, Waldmann H, Emmrich F (1995) Tolerance induction in the adult: 'danger' at Le Bischenberg. Immunol Today 16(3):121-123
13. Emmrich F, Horneff G, Becker W, Luke W, Potocnik A, Kanzy U, Kalden JR, Burmester G (1991) An anti-CD4 antibody for treatment of chronic inflammatory arthritis. Agen Act Suppl 32:165-170
14. Emmrich J, Seyfarth M, Fleig WE, Emmrich F (1991) Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 338(8766):570-571
15. Reinke P, Volk HD, Miller H, Neuhaus K, Fietze E, Herberger J, Herberger D, von Baehr R, Emmrich F (1991) Anti-CD4 therapy of acute rejection in long-term renal allograft recipients. Lancet 338(8768):702-703
16. Reinke P, Fietze E, Docke WD, Kern F, Ewert R, Volk HD (1994) Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells. Transplantation 58(1):35-41
17. Reinke P, Kern F, Fietze E, Docke WD, Ewert R, Emmrich F, Volk HD (1995) Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients - CD4+ T cells play an essential role in the rejection process. Transpl Proc 27(1):859-862
18. Laub R, Dorsch M, Meyer D, Ermann J, Hedrich HJ, Emmrich F (2000) A multiple transgenic mouse model with a partially humanized activation pathway for helper T cell responses. J Immunol Meth 246(1-2):37-50
19. Laub R, Dorsch M, Wenk K, Emmrich F (2001) Induction of immunologic tolerance to tetanus toxoid by anti-human CD4 in HLA-DR3(+)/human CD4(+)/murine CD4(-) multiple transgenic mice. Transpl Proc 33(3):2182-2183
20. Laub R, Brecht R, Dorsch M, Valey U, Wenk K, Emmrich F (2002) Anti-human CD4 induces peripheral tolerance in a human CD4+, murine CD4-, HLA-DR+ advanced transgenic mouse model. J Immunol 169(6):2947-2955
21. Strauss G, Vignali DA, Schonrich G, Hammerling GJ (1994) Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics 40(2):104-108
22. Fricke S, Ackermann M, Stolzing A, Schimmelpfennig C, Hilger N, Jahns J, Hildebrandt G, Emmrich F, Ruschpler P, Posel C, Kamprad M, Sack U (2009) Allogeneic non-adherent bone marrow cells facilitate hematopoietic recovery but do not lead to allogeneic engraftment. PLoS ONE 4(7):e6157
23. Fricke S, Fricke C, Oelkrug C, Hilger N, Schonfelder U, Kamprad M, Lehmann J, Boltze J, Emmrich F, Sack U (2010) Characterization of murine non-adherent bone marrow cells leading to recovery of endogenous hematopoiesis. Cell Mol Life Sci 67(23):4095-4106
24. Fricke S (2011) Measurement and illustration of immune interaction after stem cell transplantation. Meth Mol Biol 690:315-332
25. Fricke S, Rothe K, Hilger N, Ackermann M, Oelkrug C, Fricke C, Schonfelder U, Niederwieser D, Emmrich F, Sack U (2012) Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure. Cytom A 81(6):476-488
26. Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW (2006) Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Hematol 34(3):284-288
27. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL (1998) Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Inv 102(10):1882-1891
28. Jerome KR, Vallan C, Jaggi R (2000) The tunnel assay in the diagnosis of graft-versus-host disease: caveats for interpretation. Pathology 32(3):186-190
29. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061
30. Lange F, Hartl S, Ungethuem U, Kuban RJ, Hammerschmidt S, Faber S, Morawietz L, Wirtz H, Emmrich F, Krenn V, Sack U (2006) Anti-TNF effects on destructive fibroblasts depend on mechanical stress. Scand J Immunol 64(5):544-553
31. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucl Acids Res 30(9):e36
32. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR (1993) Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91(2):207-213
33. Hiepe F, Volk HD, Apostoloff E, von Baehr R, Emmrich F (1991) Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody. Lancet 338(8781):1529-1530
34. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H (2006) Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Prac Res Clin Haematol 19(4):825-838
35. Becker C, Bopp T, Jonuleit H (2012) Boosting regulatory T cell function by CD4 stimulation enters the clinic. Front Immunol 3:164
36. Cobbold SP (2005) T cell tolerance induced by therapeutic antibodies. Philos Trans R Soc Lond B 360(1461):1695-1705
37. Broker BM, Tsygankov AY, Fickenscher H, Chitaev NA, Muller-Fleckenstein I, Fleckenstein B, Bolen JB, Emmrich F, Schulze-Koops H (1994) Engagement of the CD4 receptor inhibits the interleukin-2-dependent proliferation of human T cells transformed by Herpesvirus saimiri. Eur J Immunol 24(4):843-850
38. Horneff G, Guse AH, Schulze-Koops H, Kalden JR, Burmester GR, Emmrich F (1993) Human CD4 modulation in vivo induced by antibody treatment. Clin Immunol Immunopathol 66(1):80-90
39. Sawitzki B, Kieselbach B, Fisser M, Meisel C, Vogt K, Gaestel M, Lehmann M, Risch K, Grutz G, Volk HD (2004) IFN-gamma regulation in anti-CD4 antibody-induced T cell unresponsiveness. J Am Soc Nephrol 15(3):695-703
40. Nagahama K, Fehervari Z, Oida T, Yamaguchi T, Ogawa O, Sakaguchi S (2009) Differential control of allo-antigen-specific regulatory T cells and effector T cells by anti-CD4 and other agents in establishing transplantation tolerance. Int Immunol 21(4):379-391
41. Yoshida H, Hashizume M, Suzuki M, Mihara M (2011) Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice. Rheumatol Int 31(11):1445-1449
42. de La Selle V, Riche N, Dorothe G, Bruley-Rosset M (1999) CD8+ cytotoxic T cell repertoire implicated in grafts-versus-leukemia effect in a murine bone marrow transplantation model. B Mar Transpl 23(9):951-958
43. Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL (1999) IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Inv 104(3):317-325